Table 1.
Clinical characteristics of COVID-19 patients included in 24 eligible studies.
| Author (year) | Origin | Design | Age (years) | Number of Patients |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | CVD | CRV | CKD | CLD | Diabetes | Hypertension | Malignancy | COPD | ||||
| Cao et al., 2019 [47] | China | NA | 54 | 102 | 5 (5%) | 6 (6%) | 4 (4%) | 2 (2%) | 11 (11 %) | 28 (28 %) | 4 (4%) | 10 (10 %) |
| Chen et al., 2020 [48] | China | RD | 62 | 274 | 23 (8%) | NA | NA | NA | 47 (17 %) | 93 (34 %) | 7 (3%) | 18 (7%) |
| Deng et al., 2020 [49] | China | RD | NA | 225 | NA | NA | NA | NA | NA | NA | NA | NA |
| Feng et al., 2020 [50] | China | RD | 53 | 476 | 38 (8%) | 17 (4%) | NA | NA | 49 (10 %) | 113 (24 %) | 12 (3%) | 22 (5%) |
| Guan et al., 2020 [51] | China | PD | 47 | 1099 | 27 (3%) | 15 (1%) | 8 (1%) | NA | 81 (7%) | 165 (15 %) | 10 (1%) | 12 (1%) |
| Huang et al., 2020 [2] | China | PD | 49 | 41 | 6 (15 %) | NA | NA | 1 (2%) | 8 (20 %) | 6 (15 %) | 1 (2%) | 1 (2%) |
| Huang et al., 2020 [52] | China | RD | 44 | 202 | NA | NA | NA | NA | 19 (9%) | 29 (14 %) | NA | NA |
| Itelman et al., 2020 [53] | Israel | RD | 52 | 162 | NA | NA | 2 (1%) | NA | 30 (19 %) | 49 (30 %) | NA | 2 (1%) |
| Javanian et al., 2020 [54] | Iran | RD | 60 | 100 | 20 (20 %) | NA | 12 (12 %) | NA | 37 (37 %) | 32 (32 %) | 4 (4%) | 12 (12 %) |
| Liu et al., 2020 [55] | China | RD | 49 | 40 | NA | NA | NA | NA | 6 (15 %) | 6 (15 %) | NA | NA |
| Shi et al., 2020 [56] | China | RD | 63 | 671 | 60 (9%) | 22 (3%) | 28 (4%) | NA | 97 (15 %) | 199 (30 %) | 23 (3%) | 23 (3%) |
| Sun et al., 2020 [57] | China | RD | 44 | 55 | NA | NA | NA | NA | 5 (9%) | 8 (15 %) | NA | NA |
| Wan et al., 2020 [58] | China | RD | 47 | 135 | 7 (5%) | NA | NA | 2 (2%) | 12 (9%) | 13 (10 %) | 4 (3%) | NA |
| Wang et al., 2020 [6] | China | RD | 56 | 138 | 20 (15 %) | 7 (5%) | 4 (3%) | 4 (3%) | 14 (10 %) | 43 (31 %) | 7 (10 %) | 4 (3%) |
| Wang et al 2020 [59] | China | RD | 51 | 107 | 13 (12 %) | 6 (6%) | 3 (3%) | 6 (6%) | 11 (10 %) | 26 (24 %) | NA | 3 (3%) |
| Wu et al., 2020 [60] | China | RD | 43 | 280 | 57 (20 %) | NA | 3 (1%) | 7 (3%) | NA | NA | 5 (2%) | NA |
| Xie et al., 2020 [61] | China | RD | 60 | 79 | 7 (9%) | NA | NA | NA | 8 (10 %) | 14 (18 %) | NA | NA |
| Xu et al., 2020 [62] | China | RD | 41 | 62 | NA | 1 (2%) | 1 (2%) | 7 (11 %) | 1 (2%) | 5 (8%) | NA | 1 (2%) |
| Xu et al., 2020 [63] | China | RD | 46 | 703 | 35 (5%) | NA | 10 (1%) | 29 (4%) | 64 (9%) | 118 (17 %) | 9 (1%) | 13 (2%) |
| Yang et al., 2020 [4] | China | RD | 59.7 | 52 | 5 (10 %) | 7 (14 %) | NA | NA | 9 (17 %) | NA | 2 (4%) | 4 (8%) |
| Zhang et al., 2020 [64] | China | RD | 57 | 140 | 7 (5%) | NA | NA | NA | 17 (12 %) | 42 (30 %) | NA | 2 (1%) |
| Zheng et al., 2020 [65] | China | RD | 45 | 161 | 4 (3%) | 4 (3%) | NA | 4 (3%) | 7 (4%) | 22 (14 %) | NA | 6 (4%) |
| Zhao et al., 2020 [66] | China | RD | 46 | 91 | NA | NA | 1 (1%) | NA | 3 (3%) | NA | 3 (3%) | 1 (1%) |
| Zhou et al., 2020 [67] | China | RD | 56 | 191 | 15 (8%) | NA | 2 (1%) | NA | 36 (19 %) | 58 (30 %) | 2 (1%) | 6 (3%) |
*Median or average age (years. Abbreviations: cardiovascular disease (CVD), cerebrovascular disease (CRV), chronic kidney disease (CKD) and chronic liver disease. (CLD), retrospective design (RD), prospective design (PD), not specified (NS), not available (NA).